Literature DB >> 12224690

Assessment of depression in subjects with psoriasis vulgaris and lichen planus.

A Akay1, A Pekcanlar, K E Bozdag, L Altintas, A Karaman.   

Abstract

AIM: The aim of this study was to investigate the frequency of depressive symptoms in psoriasis vulgaris and lichen planus and to evaluate the relationship between the Beck depression scores and the Psoriasis Area and Severity Index (PASI) scores of subjects with psoriasis vulgaris.
SUBJECTS: The study involved 120 subjects attending the dermatology clinic of Izmir Ataturk Training Hospital (Izmir, Turkey) and comprised 50 subjects with psoriasis vulgaris, 30 with lichen planus and 40 healthy control subjects.
RESULTS: Subjects with psoriasis vulgaris, lichen planus and controls had depression scores of 58%, 53% and 20%, respectively. The Beck depression scores of patients with psoriasis vulgaris were significantly higher than those of the control group. The PASI scores showed a correlation with Beck depression scores. Smoking and drinking were very common in subjects with psoriasis vulgaris. There was no correlation between the duration of illness and depressive symptoms.
CONCLUSIONS: This study confirms the importance of depressive symptoms in two common dermatological diseases. It is important to recognize this association as it affects both clinical outlook and response to treatment.

Entities:  

Mesh:

Year:  2002        PMID: 12224690     DOI: 10.1046/j.1468-3083.2002.00467.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  30 in total

Review 1.  Psoriasis and Associated Psychiatric Disorders: A Systematic Review on Etiopathogenesis and Clinical Correlation.

Authors:  Bárbara Isabel Roque Cunha Ferreira; José Luís Pio Da Costa Abreu; José Pedro Gaspar Dos Reis; Américo Manuel Da Costa Figueiredo
Journal:  J Clin Aesthet Dermatol       Date:  2016-06-01

2.  Association of salivary cortisol and anxiety levels in lichen planus patients.

Authors:  Lakshmi Kavitha Nadendla; Venkateswarlu Meduri; Geetha Paramkusam; Koteswara Rao Pachava
Journal:  J Clin Diagn Res       Date:  2014-12-05

Review 3.  Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression.

Authors:  Richard C Shelton; Andrew H Miller
Journal:  Prog Neurobiol       Date:  2010-04-22       Impact factor: 11.685

4.  Depression and the risk of psoriasis in US women.

Authors:  P L Dominguez; J Han; T Li; A Ascherio; A A Qureshi
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-10-03       Impact factor: 6.166

5.  Impact of depressive symptoms on oxidative stress in patients with psoriasis.

Authors:  Fatih Karababa; Yavuz Yesilova; Enver Turan; Salih Selek; Hacer Altun; Sahabettin Selek
Journal:  Redox Rep       Date:  2013       Impact factor: 4.412

6.  Psychological Distress, Alexithymia and Alcohol Misuse in Patients with Psoriasis: A Cross-Sectional Study.

Authors:  Ourania Founta; Karoline Adamzik; Anne-Marie Tobin; Brian Kirby; David Hevey
Journal:  J Clin Psychol Med Settings       Date:  2019-06

7.  Smoking Cigarettes and Consuming Alcohol in Patients with Psoriasis.

Authors:  Eldina Malkic Salihbegovic; Nermina Kurtalic; Esed Omerkic
Journal:  Mater Sociomed       Date:  2021-03

8.  The impact of skin involvement on the psychological well-being of patients with sarcoidosis.

Authors:  Saif Aldeen AlRyalat; Lna Malkawi; Hana Abu-Hassan; Nosaiba Al-Ryalat
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

9.  Analysis of a functional serotonin transporter promoter polymorphism in psoriasis vulgaris.

Authors:  Rotraut Mössner; Gerthild Stiens; Inke R König; Diane Schmidt; Anja Platzer; Ullrich Krüger; Kristian Reich
Journal:  Arch Dermatol Res       Date:  2008-11-01       Impact factor: 3.017

Review 10.  Mutual Relationship Between Sleep Disorders, Quality of Life and Psychosocial Aspects in Patients With Psoriasis.

Authors:  Julia Nowowiejska; Anna Baran; Iwona Flisiak
Journal:  Front Psychiatry       Date:  2021-07-06       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.